Function Health's Series B Swells to $457M with Extensions

Function Health, a company offering a membership that bundles over 160 lab tests, imaging, and a medical intelligence platform for a flat annual fee, has seen its Series B financing reach approximately $457 million. The total was driven by new extensions to the round.

The company provides an alternative to the standard annual checkup. For $365 per year, members receive testing twice annually for biomarkers covering heart and metabolic health, hormones and thyroid, cancer risks, aging, mental health, and autoimmunity. The service also provides access to MRI and CT scans, and includes the Galleri multi-cancer early detection test. Results are explained by doctors and accompanied by a personalized action plan.

The new capital will support the continued development of the company's platform, which integrates lab testing, imaging, and medical intelligence. Function Health has processed over 75 million lab results for its members and operates a network of more than 2,000 lab testing locations across the U.S. through partners like Quest Diagnostics, with at-home draws also available via Getlabs.

Function Health has drawn endorsements from prominent figures in medicine and science. Its medical and scientific board includes Mark Hyman, M.D., a former Cleveland Clinic physician who serves as the company's chief medical officer; Andrew Huberman, Ph.D., a professor of neurobiology at Stanford; Toby Cosgrove, M.D., former CEO of the Cleveland Clinic; and JoAnn E. Manson, M.D., chief of preventive medicine at Brigham and Women’s Hospital and a professor at Harvard.

The company has received recognition including being named to the TIME 100 Most Influential Companies list and Fast Company’s Most Innovative Companies. The membership is HSA/FSA eligible and is available to individuals, as well as through employer programs and as a gift.